{"schema_version":"secwatch.filing_event.v1","accession":"0001759425-25-000012","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.753707+00:00","generated_at":"2026-05-26T03:49:44.402196+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mirum reports 2024 net product sales $336.4M; guides 2025 sales $420M-$435M","bullets":["2024 net product sales $336.4M, up from $178.9M in 2023; LIVMARLI sales $213.3M, Bile Acid Medicines $123.1M.","2025 global net product sales guidance of $420M to $435M; expects positive cash flow.","Volixibat VISTAS PSC study expected to complete enrollment H2 2025; topline data in 2026.","Cash, equivalents and investments $292.8M as of Dec 31, 2024 (vs $286.3M end 2023).","CTEXLI (chenodiol) approved in US for cerebrotendinous xanthomatosis; MRM-3379 Phase 2 in FXS expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001759425-25-000012","json":"https://secwatch.observer/filing/0001759425-25-000012.json","markdown":"https://secwatch.observer/filing/0001759425-25-000012.md","text":"https://secwatch.observer/filing/0001759425-25-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000175942525000012/0001759425-25-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000175942525000012/mirm-20250226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:49:44.402196+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}